Research programme: therapeutic agents - HanAll Biopharma

Drug Profile

Research programme: therapeutic agents - HanAll Biopharma

Alternative Names: HL 152B; HL 156Can; HL 176; HL004; HL010; HL011; HL020; HL021; HL022; HL023; HL024; HL025; HL026; HL027; HL030; HL034 (oral TPO agent) - HanAll; HL038; HL039; HL051; HL076; HL102; HL130; HL156; HL157 (oral monoclonal antibody) - HanAll Biopharma; HL160; HL177; HL178-TXNIP; HL178-TXNIP (negative regulator); metformin butyrate - HanAll BioPharma; Second-generation metformin products - HanAll Biopharma

Latest Information Update: 06 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HanAll Biopharma; Korea Research Institute of Chemical Technology
  • Developer HanAll Biopharma
  • Class Monoclonal antibodies; Proteins; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Cell adhesion molecule inhibitors; Gluconeogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Angina pectoris; Asthma; Atherosclerosis; Atopic dermatitis; Cancer; Diabetes mellitus; Hypertension; Inborn genetic disorders; Obesity; Parkinson's disease; Thrombocytopenia

Most Recent Events

  • 01 Dec 2014 HanAll in-licenses OmniRat®, OmniMouse® and OmniFlic® technology from Open Monoclonal Technology
  • 24 Aug 2012 Preclinical trials in Age-related macular degeneration in South Korea (Ophthalmic)
  • 24 Aug 2012 Preclinical trials in Autoimmune disorders in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top